Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis.

Stephen L Hauser Ludwig Kappos Xavier MontalbanLicinio CraveiroCathy ChognotRichard HughesHarold KoendgenNoemi PasquarelliAshish PradhanKalpesh PrajapatiJerry S Wolinsky

Published in: Neurology (2021)

This analysis provides Class III evidence that long-term, continuous treatment with OCR has a consistent and favorable safety profile in patients with RMS and PPMS. This study is rated Class III because of the use of OLE data and historical controls.

Keyphrases

multiple sclerosis
white matter
big data
systemic lupus erythematosus
combination therapy
data analysis
smoking cessation